Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
In patients with stage IB to IIIA <i>EGFR</i> mutation-positive NSCLC, disease-free survival was significantly longer among those who received osimertinib than among those who r...